Originally published as JCO Early Release 10.1200/JCO.2004.00.9217 on September 26 2005
Journal of Clinical Oncology, Vol 23, No 30 (October 20), 2005: pp. 7565-7573
© 2005 American Society of Clinical Oncology.
Tositumomab and Iodine-131 Tositumomab Produces Durable Complete Remissions in a Subset of Heavily Pretreated Patients With Low-Grade and Transformed Non-Hodgkins Lymphomas
Richard I. Fisher,
Mark S. Kaminski,
Richard L. Wahl,
Susan J. Knox,
Andrew D. Zelenetz,
Julie M. Vose,
John P. Leonard,
Stewart Kroll,
Stanley J. Goldsmith,
Morton Coleman
From the James P. Wilmot Cancer Center, University of Rochester Medical Center, Rochester; Memorial-Sloan-Kettering Cancer Center; Weill Medical College of Cornell University, New York, NY; University of Michigan Cancer Center, Ann Arbor, MI; Johns Hopkins School of Medicine, Baltimore, MD; Stanford University Medical Center, Stanford, CA; University of Nebraska Medical Center, Omaha, NE; Corixa Corporation, Seattle, WA
Address reprint requests to Richard I. Fisher, MD, University of Rochester School of Medicine, James P. Wilmot Cancer Center, 601 Elmwood Ave, Box 704, Rochester, NY 14642; e-mail: richard_fisher{at}urmc.rochester.edu
PURPOSE: This study is an integrated efficacy analysis of the five clinical trials of tositumomab and iodine-131 tositumomab in patients with relapsed or refractory low-grade, follicular, or transformed low-grade non-Hodgkins lymphoma (NHL) that resulted in the regulatory approval of the iodine-131 tositumomab by the US Food and Drug Administration.
PATIENTS AND METHODS: This integrated analysis included 250 patients. Patients received a single course of iodine-131 tositumomab. Responses were assessed by an independent panel of radiologists and oncologists.
RESULTS: Response rates in the five trials ranged from 47% to 68%; complete response rates ranged from 20% to 38%. With a median follow-up of 5.3 years, the 5-year progression-free survival was 17%. Eighty-one (32%) of 250 patients had a time to progression of 1 year (termed durable response population). For the durable response population, 44% had not progressed at 2.5 to 9.5 years and had a median duration of response of 45.8 months. The median duration of complete response was not reached. The durable response population had many poor prognostic characteristics, including bone marrow involvement (41%), bulky disease 5 cm (49%), and transformed histology (23%). Forty-three percent of the patients had been treated with more than four prior therapies and 36% had not responded to their most recent therapy.
CONCLUSION: The tositumomab and iodine-131 tositumomab therapeutic regimen produces high response rates in patients with relapsed or refractory low-grade, follicular, and transformed low-grade NHL, with a sizable subgroup of patients achieving long-term durable responses.
Supported by Corixa and GlaxoSmithKline, in the conduct of the research reported in this article.
This original manuscript has not been previously published.
Authors disclosures of potential conflicts of interest are found at the end of this article.
This article has been cited by other articles:

|
 |

|
 |
 
R. M. Sharkey, H. Karacay, S. Litwin, E. A. Rossi, W. J. McBride, C.-H. Chang, and D. M. Goldenberg
Improved Therapeutic Results by Pretargeted Radioimmunotherapy of Non-Hodgkin's Lymphoma with a New Recombinant, Trivalent, Anti-CD20, Bispecific Antibody
Cancer Res.,
July 1, 2008;
68(13):
5282 - 5290.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. P. Plastaras, E. Glatstein, and S. J. Schuster
Commentary: Let the Tail Wag the Dog: The Case for Radioimmunotherapy of Low-Grade Follicular Lymphoma
Oncologist,
June 1, 2008;
13(6):
655 - 656.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
F. Buchegger, O. W. Press, A. B. Delaloye, and N. Ketterer
Radiolabeled and Native Antibodies and the Prospect of Cure of Follicular Lymphoma
Oncologist,
June 1, 2008;
13(6):
657 - 667.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. A. Jacene, R. Filice, W. Kasecamp, and R. L. Wahl
Comparison of 90Y-Ibritumomab Tiuxetan and 131I-Tositumomab in Clinical Practice
J. Nucl. Med.,
November 1, 2007;
48(11):
1767 - 1776.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. Martin, R. R. Furman, M. Coleman, and J. P. Leonard
Phase I to III Trials of Anti B Cell Therapy in Non Hodgkin's Lymphoma
Clin. Cancer Res.,
September 15, 2007;
13(18):
5636s - 5642s.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Nabhan
It Is Follicular... . So, Why CHOP?
J. Clin. Oncol.,
March 1, 2007;
25(7):
915 - 916.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. Song, Y. Du, G. Sgouros, A. Prideaux, E. Frey, and R. L. Wahl
Therapeutic Potential of 90Y- and 131I-Labeled Anti-CD20 Monoclonal Antibody in Treating Non-Hodgkin's Lymphoma with Pulmonary Involvement: A Monte Carlo-Based Dosimetric Analysis
J. Nucl. Med.,
January 1, 2007;
48(1):
150 - 157.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. M. Sharkey and D. M. Goldenberg
Targeted Therapy of Cancer: New Prospects for Antibodies and Immunoconjugates
CA Cancer J Clin,
July 1, 2006;
56(4):
226 - 243.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|